Denmark urges EU to tighten Russian visa restrictions after alleged assassination plot
Denmark has urged European Union countries to introduce tougher travel restrictions on Russian nationals following allegations that Moscow's in...
AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
European leaders backing Ukraine met in Berlin on Thursday 19 November and warned that no peace deal should be settled without them.
Three people have been killed and around 15 injured after Russian ballistic missiles struck three bridges over the Dnipro River in Kyiv, according to the Ukrainian capital’s mayor, Vitali Klitschko.
Azerbaijani President Ilham Aliyev met Vietnamese Prime Minister Le Minh Hung in Hanoi on 20 November, during a visit highlighting the longstanding friendship and growing strategic partnership between the two countries.
Britain and the European Union have reached an agreement to ease trade, expand opportunities for young people and deepen economic ties, in a major step towards rebuilding relations after Brexit.
Georgia has declared 22 November 2026 a national day of mourning following a deadly residential building collapse in the Kvemo Ponichala district of Tbilisi.
For the first time in more than a quarter of a century, the United States can no longer say it has eliminated measles as health experts warn the American outbreak reflects a collapse in trust in vaccines.
A new study in mice suggests the brain’s protective barrier does more than block harmful substances. It also delivers essential proteins from the body, a process that may break down early in Alzheimer’s disease and offer a new target for treatment.
Here's your AnewZ Daily Brief for the 5th of November, as health emergencies, humanitarian crises, political shifts, and cybersecurity threats put governments and essential services under pressure across the globe. Here are five stories worth your attention.
Kazakhstan plans to manufacture 494 types of medicines through eight major investment projects worth a combined $862 million, Health Minister Akmaral Alnazarova announced on 3 November, local media reported.
Dengue fever has killed more people in Bangladesh this year than in the whole of 2025, with October the deadliest month so far, data from Bangladesh's Health Ministry shows.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment